<DOC>
	<DOCNO>NCT03066219</DOCNO>
	<brief_summary>The objective study compare safety efficacy BRM421 Ophthalmic Solution placebo treatment sign symptom dry eye .</brief_summary>
	<brief_title>Safety Efficacy BRM421 Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age ; Provide write informed consent ; Have report history dry eye least 6 month prior enrollment ; Have history use eye drop Have clinically significant slit lamp finding Visit 1 may include active blepharitis , meibomian gland dysfunction ( MGD ) , lid margin inflammation active ocular allergy require therapeutic treatment , and/or opinion investigator may interfere study parameter ; Be diagnose ongoing ocular infection ( bacterial , viral , fungal ) , active ocular inflammation Visit 1 ; Have wear contact lenses within 7 day Visit 1 anticipate use contact lens study ; Have use eye drop within 2 hour Visit 1 ; Have previously laserassisted situ keratomileusis ( LASIK ) surgery within last 12 month ; Be woman childbearing potential use acceptable mean birth control ; acceptable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>